MitoQ (mitoquinone or mitoquinol mesylate) is an antioxidant joined to a fat-soluble, positively charged molecule that makes it build up several hundred-fold inside mitochondria. It is sold as a supplement.
Also known as: mitoquinone, mitoquinol mesylate, mitoquinone mesylate.
Trials in older adults used 20 mg a day for 6 to 8 weeks (Rossman 2018, Stute 2026); a hepatitis C trial used 40 or 80 mg a day for 28 days (Gane 2010). These are study protocols, not a recommendation.
The NIH Dietary Supplement Label Database lists MitoQ, from the company of the same name, as a dietary supplement. Under the 1994 dietary supplement law (DSHEA), FDA does not approve dietary supplements before they are marketed, and the maker, not FDA, is responsible for safety and labeling. Drugs@FDA lists no approved mitoquinone product.
What studies show: in a 12-month trial in 128 people newly diagnosed with Parkinson's disease, two doses of MitoQ did not slow progression on any measure compared with placebo (Snow 2010). In a 6-week crossover trial in 20 healthy adults aged 60 to 79 with impaired blood vessel function, 20 mg a day improved artery dilation (flow-mediated dilation) by 42% versus placebo and lowered aortic stiffness in those who started high (Rossman 2018). In 30 people with hepatitis C, liver enzymes fell from baseline over 28 days, but the difference from placebo was not significant and viral load did not change (Gane 2010).
Safety: MitoQ was well tolerated in the 6-week trial (Rossman 2018), and 8 weeks of 20 mg a day did not change kidney function or kidney injury markers in 30 middle-aged and older adults (Stute 2026). The sources here do not describe drug interactions.
We could not find a single published half-life or time to peak for MitoQ that applies to a supplement dose, so we do not list one.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator